IBDEI1EI ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25123,0)
 ;;=288.09^^145^1535^8
 ;;^UTILITY(U,$J,358.3,25123,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25123,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,25123,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,25123,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,25124,0)
 ;;=V10.21^^145^1535^61
 ;;^UTILITY(U,$J,358.3,25124,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25124,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,25124,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,25124,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,25125,0)
 ;;=284.2^^145^1535^106
 ;;^UTILITY(U,$J,358.3,25125,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25125,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,25125,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,25125,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,25126,0)
 ;;=202.40^^145^1535^76
 ;;^UTILITY(U,$J,358.3,25126,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25126,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,25126,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,25126,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,25127,0)
 ;;=287.49^^145^1535^118
 ;;^UTILITY(U,$J,358.3,25127,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25127,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,25127,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,25127,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,25128,0)
 ;;=180.9^^145^1535^29
 ;;^UTILITY(U,$J,358.3,25128,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25128,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,25128,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,25128,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,25129,0)
 ;;=203.02^^145^1535^104
 ;;^UTILITY(U,$J,358.3,25129,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25129,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,25129,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,25129,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,25130,0)
 ;;=204.02^^145^1535^2
 ;;^UTILITY(U,$J,358.3,25130,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25130,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,25130,1,5,0)
 ;;=5^ALL,In Relapse
 ;;^UTILITY(U,$J,358.3,25130,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,25131,0)
 ;;=204.12^^145^1535^17
 ;;^UTILITY(U,$J,358.3,25131,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25131,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,25131,1,5,0)
 ;;=5^CLL,In Relapse
 ;;^UTILITY(U,$J,358.3,25131,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,25132,0)
 ;;=204.20^^145^1535^114
 ;;^UTILITY(U,$J,358.3,25132,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25132,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,25132,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,25132,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,25133,0)
 ;;=204.21^^145^1535^116
 ;;^UTILITY(U,$J,358.3,25133,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25133,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,25133,1,5,0)
 ;;=5^Subacute LL,In Remission
 ;;^UTILITY(U,$J,358.3,25133,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,25134,0)
 ;;=204.22^^145^1535^115
 ;;^UTILITY(U,$J,358.3,25134,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25134,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,25134,1,5,0)
 ;;=5^Subacute LL,In Relapse
 ;;^UTILITY(U,$J,358.3,25134,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,25135,0)
 ;;=205.02^^145^1535^5
 ;;^UTILITY(U,$J,358.3,25135,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25135,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,25135,1,5,0)
 ;;=5^AML,In Relapse
 ;;^UTILITY(U,$J,358.3,25135,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,25136,0)
 ;;=205.12^^145^1535^20
 ;;^UTILITY(U,$J,358.3,25136,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25136,1,4,0)
 ;;=4^205.12
